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Breast cancer, along with cervical cancer, is one of the most commonly
diagnosed cancers of pregnancy. Most would define gestational breast can-
cer as breast cancer that is diagnosed during pregnancy, lactation, and up to
12 months post-partum. The diagnostic and therapeutic implications in this
clinical setting are special. These women typically present with a more ad-
vanced-stage disease that carries an associated poorer prognosis. Physicians
thus are challenged to balance aggressive maternal care with appropriate
modifications that will ensure fetal protection.
Epidemiology
Based on the National Cancer Institute’s Surveillance, Epidemiology, and
End Results Program Cancer Statistics Review and rates from 2001 to 2003,
12.67% of women will develop breast cancer during their lifetime. This life-
time risk translates into one in eight women. Additionally, this review notes
that the mean age at diagnosis for breast cancer from 2000 to 2003 was 61
years, and only approximately 12.7% of women were between the ages of
20 and 44 [1]. Of women diagnosed with breast cancer younger than 40 years,
only approximately 10% will be pregnant [2,3]. These data certainly suggest
a low incidence of pregnancy-associated breast cancer. In fact, historically,
the incidence is estimated at 1 in 3000 pregnancies [4–6]. Despite the overall
low incidence, however, gestational breast cancer is one of the most common
pregnancy-associated malignancies, second only to cervical cancer [4,6].
Notably, many have offered that this incidence will only increase as more
women delay childbearing until later in life [4,7]. This concern is based on
the fact that pregnancy-associated breast cancer is age-related, and women
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418 BARNES & NEWMANwho have their first term pregnancy after the age of 30 years have a two to
three times higher risk of developing breast carcinoma than women who
have their first pregnancy before the age of 20 years [8]. Presently, most stud-
ies support a mean age at diagnosis of 32 to 34 years [8–11].
Prognosis
Clinical staging of these patients does not waver from the TNM staging
system of the American Joint Committee on Cancer. Historically preg-
nancy-associated breast cancer was thought to be rapid in course, exces-
sively malignant, and incurable [12,13]. More recently, the prognosis of
gestational breast cancer has been shown to be similar to that of nonpreg-
nant women when age and stage at presentation are accounted for
(Table 1) [4,14,15]. Notably, both Anderson and colleagues [16] and Ishida
and colleagues [9] document no difference in the prognosis of early cancers
(when matched for age and stage), but a poorer prognosis is demonstrated
for patients with more advanced disease. Numerous studies have docu-
mented that these women present with larger tumors and have a higher in-
cidence of lymph node metastases (56% to 89% when compared with 38%
to 54% in nonpregnant young women) that appears to translate into a more
advanced stage [7–9,17–21]. Most women present with stage II or III disease
(65% to 90% compared with 45% to 66% of nonpregnant controls) [8,9,17].
Table 2 references the 5- and 10-year survival for node-negative and
node-positive disease for pregnancy-associated breast cancer as 60% to
100% and 31% to 52% respectively [7,22,23]. A delay in diagnosis, on the
part of physician and patient alike, is thought to contribute to the advanced
disease at presentation. This in part, is attributed to the engorgement and
physiologic hypertrophy of the pregnant or lactating breast. It is no longer
accepted that pregnancy is an independent risk factor for poor prognosis,
and there is no clear evidence to support that the hyperestrogenic state of
pregnancy contributes to development and rapid growth [24].
Pathology
Table 3 references the general pathology of pregnancy-associated breast
cancer. Invasive ductal carcinoma predominates. As mentioned previously,
these tumors are typically larger in size at presentation. Additionally, there
is a higher frequency of lymphovascular invasion, high nuclear grade, and
hormone independence. These histopathologic and immunohistochemical
features are similar to those of nonpregnant young women with breast
cancer, and they are felt to be determined by the age of diagnosis rather
than pregnancy [4,25,26].
The degree of hormone receptor status negativity is consistently greater
in the pregnant cohort of young women diagnosed with breast cancer.
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420 BARNES & NEWMANestrogen and progesterone in pregnancy may occupy all of the hormone re-
ceptor binding sites; the second relates to receptor down-regulation during
pregnancy [7,9,27,28].
Additionally, a retrospective and multi-institutional study from Bonnier
and colleagues [27] found immunohistochemical assessment of hormone
receptor status to be more reliable than a ligand-based assay. Ligand-based
assays depend upon the availability of unbound hormone receptors, which
may be less accurate during pregnancy secondary to interference by circulat-
ing steroid receptors. Finally, there is no consensus regarding the prevalence
or implication of HER-2/neu overexpression in pregnancy-associated breast
cancer.
Diagnostic evaluation
Most women diagnosed with pregnancy-associated breast cancer will
present with a painless mass in the breast. A milk-rejection sign has been
described rarely in case reports when a nursing infant refuses a lactating
breast that harbors occult carcinoma [29,30]. The differential diagnosis of
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Selected studies comparing 5-year survival rates, considering nodal status
Author/date Node-negative (n) Node-positive (n)
King et al/1985 [22] 82% (22) 36% (36)
Nugent and O’Connell/1985 [2] 100% (4) 50% (15)
Petrek et al/1991 [18] 82% (22) 47% (34)
Ishida et al/1992 [9] 90% (71) 52% (101)
Kuerer et al/1997 [23] 60% (14) 45% (12)
Bonnier et al/1997 [27] 63% (50) 31% (64)
Reed et al/2003 [17] 62% (31) 40% (69)
n ¼ sample size.
Table 3
Selected studies examining pathologic features of pregnancy-associated breast cancer
Au þ) % Assay Her-2/neu (þ) %
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422 BARNES & NEWMANAlthough 80% of these masses are benign, further evaluation is war-
ranted if findings persist more than 2 to 4 weeks [7,32]. Evaluation begins
with a thorough clinical examination, and a baseline breast examination is
recommended at the first prenatal visit [4].
Mammography in young nonpregnant and nonlactating women (!35
years) often reveals dense breast parenchyma, contributing to the recom-
mendation that mammography should not be employed for routine screen-
ing purposes in this patient population. As breast size and parenchymal
density increase during pregnancy and lactation secondary to hyperestro-
genic proliferative changes, the corresponding efficacy of mammography
historically has been questioned [7]. More recently, both the safety and
efficacy of mammography during pregnancy have been supported, and
mammographic sensitivity rates of 78% to 90% have been documented
[33–36]. A retrospective review by Yang and colleagues [33] of 20 pregnant
patients imaged during pregnancy preoperatively found mammography to
be 90% sensitive in detecting suspicious features of malignancy. Impor-
tantly, 33% of these tumors exhibited secondary features of malignancy,
considered to be more subtle (ie, increased breast density and architectural
distortion) and felt to contribute to the false-negative rate associated with
mammography during pregnancy [33]. Regarding the risk of fetal irradia-
tion, with proper abdominal shielding, the estimated fetal dose of radiation
from a standard two-view mammogram (200 to 400 mrad) is less than 0.004
Gy [7]. This is negligible and well below the threshold exposure of the
100 mGy that is associated with a 1% risk of fetal malformation and central
nervous system problems as published by the International Commission of
Radiological Protection [37].
Ultrasound offers an excellent adjuvant role in the early work-up of
a breast mass with no risk of fetal irradiation. The same study by Yahg
and colleagues noted ultrasound to be 100% sensitive in detecting a breast
mass correlating with a palpable abnormality, supporting previously pub-
lished data [33,35,36]. Additionally, ultrasound detected additional tumors
in the breast in 20% of patients in this same series, and detected axillary
metastases in 83% of those imaged (supported by US-guided fine needle as-
piration [FNA]) [33]. It appears to be complimentary for staging and detect-
ing mammographic false-negative disease, and it may aid in the assessment
of response to neoadjuvant therapy [33].
Further acceptable imaging modalities for staging, as clinically indicated,
include chest radiograph with abdominal shielding (fetal irradiation exposure
!0.01 mGy), abdominal ultrasound or MRI and thoracic/lumbar MRI. As
Gandolinium crosses the placenta and is associated with fetal abnormalities
in rats (Category C), contrast-enhanced MRI is not recommended [4,7,37].
A routine bone scan results in 4.7 to 1.8 mGy of fetal exposure, which varies
with gestational age; this is not recommended during pregnancy [4,37].
Despite negative findings on breast imaging, pathologic diagnosis with
biopsy is recommended for persistent masses, as with breast cancer in general.
423PREGNANCY-ASSOCIATED BREAST CANCERFNA, core needle biopsy, and excisional biopsy are all reasonable modalities.
Historically pregnancy-related hyperplastic changes with atypia were
thought to result in false-positive FNA results; however, several authors
have demonstrated marked accuracy and a reduction in surgical biopsy rates
when performed by a skilled pathologist made aware of the patient’s pregnant
or lactating state [38–41]. Core needle and excisional biopsymay be employed
also. There are only case reports to support the frequency of milk fistula as
a complication, and this may be reduced by emptying the breast of milk
before biopsy with ice packs, breast binding, and bromocriptine [7,42].
Management
There is no longer a role for therapeutic abortion. The therapeutic
approach to pregnancy-associated breast cancer is similar to that in nonpreg-
nant women: to achieve local control of disease and prevent systemic metas-
tases. Treatment guidelines for nonpregnant patients are followed, allowing
for fetal-protective modifications. Each patient’s approach must be individ-
ualized, taking into account gestational age at presentation, patient’s stage of
disease, and patient preference [4]. A multidisciplinary approach should be
embraced, allowing for close coordination between medical oncology, surgi-
cal oncology, and high-risk obstetrics. Genetic counseling is recommended
for all women. The need for psychological support is emphasized.
Surgery
The safety of surgical intervention during pregnancy is well supported, but
it may be deferred until the 12th gestational week given that the risk of
spontaneous abortion is greatest during the first trimester [7,11,24,43,44].
Historically, a modified radical mastectomy was considered the standard
of care for all resectable disease during each trimester. This approach both
eliminates the need for breast irradiation and definitively manages the axilla.
Breast conservation therapy (BCT) increasingly is offered to these young
women, although limited by the risks of fetal irradiation postoperatively.
Although lumpectomy is considered safe during all trimesters, the required
postoperative therapeutic irradiation necessary to complete BCT and obtain
optimal local control is considered contraindicated during all trimesters.
Appropriate candidates for BCT include women diagnosed late in the second
trimester or third trimester so that radiation therapy may be deferred until
after delivery, and those women with advanced-stage disease in which neo-
adjuvant therapy may acceptably delay definitive local resection [4].
Irradiation
Fetal radiation risks are most significant during the first trimester (before
the completion of organogenesis) and least during the third trimester. Risks
424 BARNES & NEWMANinclude teratogenicity, spontaneous abortion and childhood neoplasia, and
hematologic disorders. During weeks 2 to 8, during organogenesis, fetal
malformations may arise with exposure to a threshold dose greater than
100 to 200 mGy [37,45]. During weeks 8 to 25, the central nervous system
is especially sensitive to radiation, and exposure to a threshold dose of 0.1
to 0.2 Gy may decrease the intelligent quotient (IQ), while fetal exposure
to 1 Gy increases the probability of severe mental retardation [37,45].
Additionally, fetal exposure to 0.01 Gy increases the incidence of spontane-
ous childhood cancer and leukemia by 40% (over a background risk of three
to four per 1000) [37,45].
The typical dose for therapeutic breast or chest wall irradiation is 50
Gy; this results in fetal exposure of 0.05 to 0.15 Gy and up to 2 Gy toward
the end of gestation as the fetus lies closer to the irradiated field in posi-
tion [45–47]. Notably, there have been case reports of normal infants born
to irradiated mothers and successful radiation therapy for Hodgkin disease
during pregnancy with appropriate supplemental shielding [32,45,47–49].
Additionally, the 2006 international recommendations from an expert
meeting published by Loibl and colleagues [4] regarding therapeutic irradi-
ation have recently been challenged by authors who feel the risks of fetal
irradiation exposure have been overestimated [49]. These authors present
that the fetal dose caused by leakage radiation from the tube head of
the linear accelerator and scatter from collimator and blocks can be re-
duced with a factor two to four by proper shielding, thereby keeping the
radiation dose below the threshold dose for deterministic effects in most
cases [49].
Management of the axilla
Appropriate interrogation and management of the axilla are necessary to
ensure correct staging at the time of presentation and to drive the appropri-
ate definitive therapy. As mentioned previously, these women present with
an increased frequency of nodal involvement. Notably, the early diagnosis
of axillary metastases may increase patient stage such that she becomes an
acceptable candidate for neoadjuvant chemotherapy, thereby allowing for
BCT [4]. Certainly, axillary ultrasound with sonographic-guided FNA of
suspicious nodes may be helpful in diagnosing metastatic disease [33]. Cur-
rently, axillary lymph node dissection remains the standard of care for these
women.
Intraoperative lymph node mapping and sentinel lymph node biopsy re-
main controversial for two reasons. First, Isosulfan blue dye is classified as
a pregnancy category C drug and subsequently is not recommended in these
patients. The sensitivity of sentinel lymph node biopsy is reduced when us-
ing only the radiocolloid to guide mapping [4]. Second, there are justifiable
concerns regarding the risk of fetal irradiation with the use of a radiocolloid
in pregnancy, specifically 99mTc-Sulfur Colloid [50,51].
425PREGNANCY-ASSOCIATED BREAST CANCERNicklas and Baker suggested that sentinel lymph node biopsy might be
safe during pregnancy with a minimal dose of 500 to 600 mCi using dou-
ble-filtered 99mTc-Sulfur Colloid [7,51]. Several publications have followed
to support that fetal radiation exposure from this procedure is actually quite
minimal and that sentinel lymph node biopsy may serve more of a role during
pregnancy. Using two nonpregnant patient exposures, Keleher and col-
leagues [52] in 2004 estimated the maximum absorbed dose to the fetus/em-
bryo in pregnant women undergoing breast lymphoscintigraphy with
92.5MBq (2.5mCi) of 99mTc-Sulfur Colloid as 4.3 mGy using the Medical
Internal Radiation Dosimetry (MIRD) program. The same year, Gentilini
and colleagues [53] measured activity using thermoluminescent dosimeters
combined with static and whole-body scintigraphic imaging in 26 nonpreg-
nant patients exposed to lymphoscintigraphy and overestimated the fetal
absorbed dose as 61 mGy. In 2006, Pandit-Taskar and colleagues [54] retro-
spectively assessed the absorbed doses to various organs and a modeled
fetus using standard internal absorbed dose assessment methodologies and
phantom models in 1021 nonpregnant women undergoing sentinel node
mapping and biopsy and estimated the absorbed fetal dose as 14 mGy.
Finally, also in 2006, Mondi and colleagues [50] reviewed one institution’s
experience with sentinel node mapping and biopsy during pregnancy for
breast cancer and melanoma. Although limited (n ¼ 9), the review noted
no adverse reactions to the procedure itself; all pregnancies were delivered
at term. Additionally, there have been no birth defects or discernable
malformations.
It is unclear whether the lymphatic drainage of the breast is altered by
pregnancy, but there is no evidence to support this [50,55]. Additionally,
sentinel lymph node biopsy in pregnancy has not been evaluated systemat-
ically. The estimated fetal absorbed dose of radiation, however, is negligible,
and recent recommendations from an international expert panel meeting in
2006 suggest that pregnant patient could be offered sentinel lymph node bi-
opsy after extensive counseling regarding the amount of radiation involved,
the overall safety, and efficacy [4].
Systemic therapy
Chemotherapy serves an important role in adjuvant and neoadjuvant
therapy for patients who have pregnancy-associated breast cancer,
especially as so many will present with advanced-stage disease. Although
all chemotherapy agents used in the treatment of breast cancer in pregnancy
are Category D (ie, teratogenic effects have occurred in people), a surprising
safety profile has been demonstrated if administered outside of the first tri-
mester [4,7,11,56–62]. Most frequently documented complications included
preterm delivery, low birth weight, transient leukopenia of the newborn,
and intrauterine growth restriction. Doll and colleagues [59] in 1989 note
that the incidence of fetal malformations with first-trimester chemotherapy
426 BARNES & NEWMANwith various agents ranged from 14% to 19%. This value compared with the
1.3% incidence of fetal malformations associated with chemotherapy
administered in the second and third trimesters.
The largest prospective series of pregnancy-associated breast cancer
treated with cytotoxic chemotherapy in the second and third trimesters
initially included 24 women and came from the University of Texas M.D.
Anderson Cancer Center. In 1999 Berry and colleagues [56] evaluated the
treatment of pregnancy-associated breast cancer with 5-Fluorouracil,
Doxorubicin, and Cyclophosphamide (FAC: 500 mg/m2 5-fluorouracil
days 1 þ 4; 50 mg/m2 continuous 72-hour infusion of Doxorubicin days 1
through3; 500mg/m2 Cyclophosphamide day 1 of a 3-week cycle). This group
reported no antepartum complications temporally attributed to systemic
therapy and supported that Apgar scores, birth weights, and immediate
postpartum health were normal for all children.
This data set expanded and was published recently by Hahn and
colleagues [11] in September 2006. Fifty-seven women who had pregnancy-
associated breast cancer were treated with FAC in the second and third
trimesters, and parents/guardians were surveyed for longer-term follow-up
(median follow-up duration 38.5 months). The authors reported no still-
births, miscarriages, or perinatal deaths related to therapy. Only three
patients delivered before 34 weeks gestational age, one being less than 29
weeks and associated with maternal preeclampsia. Only 6 children weighed
less than 2500g. The most common documented neonatal complication was
difficulty breathing, and 10% of neonates required mechanical ventilation.
One child had a subarachnoid hemorrhage on postpartum day 2, coinciding
with thrombocytopenia (platelet count 89 K/UL), and neutropenia. Finally,
one child was born with Down syndrome. Only 2 of the 18 school-aged
children required special attention at school, and the rest were thought to
exhibit normal development [56].
There still remains a concern for anthracycline-associated fetal cardiotox-
icity as children and adults reliably demonstrate a dose-dependent risk of
cardiomyopathy with exposure. There have been several studies that
support neonatal cardiac effects and in utero fetal death after exposure to
idarubicin or epirubicin (among other agents) [62–64]. For this reason, Car-
donick and colleagues endorse the use of doxorubicin rather than the afore-
mentioned agents [60]. Meyer-Wittkopf and colleagues [65] performed fetal
echocardiograms every 2 weeks in pregnant patients receiving doxorubicin
and cyclophosphamide starting at 24 weeks. Using unexposed fetuses aged
20 to 40 weeks for comparison; the authors identified no notable
difference in systolic function between the study and control groups. In
fact, postnatal echocardiograms repeated until 2 years of age demonstrated
no myocardial damage. Additionally, Peccatori and colleagues [66] support
that epirubicin is preferable clinically in this setting given its better therapeu-
tic index, fewer systemic and cardiac toxic effects, and shorter terminal half-
life. These same authors relay their experience with epirubicin-based
427PREGNANCY-ASSOCIATED BREAST CANCERregimens for pregnancy-associated breast cancer and report no severe
maternal or fetal complications, only one case of vesicoureteral reflux,
mirroring other authors’ experiences [66–68].
Methotrexate is a known abortifacient, and it should be avoided during
pregnancy [7,58]. There are several case reports that support the safety of
taxanes in treating pregnancy-associated breast cancer, but nothing to sup-
port the safety of dose dense anthracycline therapy with or without taxanes
during pregnancy [69–73]. Finally, there are only case reports documenting
the use of trastuzumab on pregnancy. Watson describes a case of reversible
anhydramnios, while two other case reports report no immediate fetal or
neonatal complications [74–76]. Tamoxifen therapy during pregnancy has
been associated with ambiguous genitalia and Goldenhar’s syndrome while
other authors note no fetal/neonatal complication [77–82]. Tamoxifen is not
recommended during gestation [4].
Present recommendations for chemotherapy dosing in pregnancy are
weight-based. This dosing, however, may be complicated by increased
plasma volume, increased hepatorenal function, decreased albumin concen-
tration, decreased gastric motility, and the theoretical possibility of amniotic
sac third-spacing [7]. Also, chemotherapy should be avoided 3 to 4 weeks
before delivery (following the mother’s nadir) to reduce the risk of infectious
complications and hemorrhage from pancytopenia [7,60].
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